Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813682 | 1.00 | CNR1 (0.46) | CNR1CNR2F2KMT2ARAB9A | |
| SCHEMBL18878678 | 0.95 | F2 (0.41) | CNR1CNR2F2KMT2ARAB9A | |
| SCHEMBL18875644 | 0.95 | F2 (0.41) | CNR1CNR2F2KMT2ARAB9A | |
| SCHEMBL7022185 | 0.95 | F2 (0.41) | CNR1CNR2F2KMT2ARAB9A | |
| SCHEMBL18875713 | 0.95 | F2 (0.41) | CNR1CNR2F2KMT2ARAB9A | |
| SCHEMBL4901979 | 0.95 | F2 (0.41) | CNR1CNR2F2KMT2ARAB9A | |
| SCHEMBL18875724 | 0.95 | F2 (0.41) | CNR1CNR2F2KMT2ARAB9A | |
| SCHEMBL18875527 | 0.95 | F2 (0.41) | CNR1CNR2F2KMT2ARAB9A | |
| SCHEMBL18875546 | 0.95 | F2 (0.41) | CNR1CNR2F2KMT2ARAB9A | |
| SCHEMBL18875725 | 0.95 | F2 (0.41) | CNR1CNR2F2KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7335672-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335672-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335672-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1877400-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen, Inc (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7301022-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7301022-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7301022-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1802605-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Amgen, Inc (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1789413-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006113769-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060235036-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-10-19 | — | — | US | disclosed |
| WO-2006089311-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-08-17 | — | — | US | disclosed |
| WO-2006044527-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2006031852-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235036-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CNR1 391/4885CNR2 171/4885F2 3901/4885 |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | CNR1 297/4885CNR2 111/4885F2 3601/4885 |
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | CNR1 554/4885CNR2 210/4885F2 4318/4885 |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CNR1 391/4885CNR2 171/4885F2 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.